Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.61)
# 3,067
Out of 4,944 analysts
31
Total ratings
48.15%
Success rate
-9.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $65.14 | +36.63% | 3 | Aug 8, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $50 → $20 | $2.97 | +573.40% | 3 | Jul 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.02 | +147.52% | 1 | Apr 29, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $204 → $205 | $201.47 | +1.75% | 3 | Apr 28, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $9.97 | +130.69% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $1.71 | +250.88% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $646.60 | +9.19% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $20.40 | +733.33% | 9 | Nov 7, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $5.17 | +286.85% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $149.36 | +37.92% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.70 | +1,194.12% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.33 | +329.18% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $23.21 | +158.51% | 1 | Oct 5, 2022 |
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $65.14
Upside: +36.63%
Jasper Therapeutics
Jul 8, 2025
Maintains: Outperform
Price Target: $50 → $20
Current: $2.97
Upside: +573.40%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.02
Upside: +147.52%
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $204 → $205
Current: $201.47
Upside: +1.75%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $9.97
Upside: +130.69%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $1.71
Upside: +250.88%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $646.60
Upside: +9.19%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $20.40
Upside: +733.33%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.17
Upside: +286.85%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $149.36
Upside: +37.92%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.70
Upside: +1,194.12%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.33
Upside: +329.18%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $23.21
Upside: +158.51%